Rapid Recognition of Corticosteroid Resistant or Sensitive Sepsis
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 1,800 people, planned
- Started
- 10 Apr 2020
- Planned end
- Dec 2025
- Type of study
- Interventional, 12 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Administration procedures
- Record updated
- 1 October 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Patient ≥18 years old
- Admitted to ICU with proven or suspected infection as the main diagnosis
- Community acquired pneumonia related sepsis or vasopressors dependency (norepinephrine, epinephrine, vasopressin, dopamine, phenylephrine) or septic shock (vasopressor to maintain mean blood pressure of at least 65 mmHg and lactate levels above 2 mmol/l) or acute respiratory distress syndrome (ARDS: a- acute onset, i.e. within one week of an apparent clinical insult and with progression of respiratory syndrome, b- bilateral opacities on chest imaging not explained by other pulmonary pathologies, e.g. pleural effusion, atelectasis, nodules etc, c- no evidence for heart failure or volume overload, d- PaO2/FiO2 ≤ 300 mm Hg, - PEEP ≥ 5 cm H2O
- Patients who have been tested for one or more RECORDS specific biomarkers:; CIRCI; Endocan; GILZ; DUSP-1; MDW; lymphopenia; Transcriptomic SRS2; Endotype B; PCR COVID-19; PCR Influenza; PCR other respiratory virus; Cutaneous vasoconstrictor response to glucocorticoids
- Patient who has signed an informed and written consent whevener he/she is able of consent, if not, if not ascent from his/her representant whenever he/she is present at time of screening for inclusion
- Patient affiliated to a social security system or to an universal health coverage (Couverture Maladie Universelle (CMU) in France
- Patient under guardianship or curatorship will be included
- Patient in case of simple emergency (legal definition) will be included
- Patients managed with covid 19 and having biological samples available
Who cannot take part
- Previously enrolled in this study
- Formal indication for corticosteroids according to most recent international guidelines
- Hypersensitivity to hydrocortisone or fludrocortisone or (microsined betamethasone dipropionate*) or any of their excipients (spc)
- Nursing women * For patients included in this stratum, if applicable, do not apply the cream to an infected or ulcerated area
- Pregnancy
- Expected death or withdrawal of life-sustaining treatments within 48 hours
- Vaccination with live virus within past 6 months
- Women of childbearing potential not using contraception
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Main objective and primary endpoint: To compare the effect hydrocortisone plus fludrocortisone vs. placebo on a composite of death or persistent organ dysfunction - defined as continued dependency on mechanical ventilation, new renal replacement therapy, or vasopressors - assessed at 90 days on intensive care unit (ICU) adults and having different biological profiles for immune responses and corticosteroids bioactivity.
Read full original descriptionShow less
Secondary objectives and endpoints:
* Mortality and health-related quality of life at 6 months; * Daily organ function (SOFA score days 1, 2, 3, 4, 7, 10, 14, 28, and 90); * Daily secondary infections (up to 90 days) * Daily blood and urinary levels of glucose, sodium and potassium (up to 28 day) * Daily gastroduodenal bleeding (up to 28 day) * Daily cognitive function and muscles' strength (days 1 to 28, 90 and 180 days).
The 12 groups in the trial
- Biomarker CIRCI neg: Corticosteroid armTreatment being tested
Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
Treatment: Administration procedures
- Biomarker CIRCI neg: Placebo armPlacebo, for comparison
Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
Treatment: Administration procedures
- Biomarker endocan: Corticosteroid armTreatment being tested
Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
Treatment: Administration procedures
- Biomarker endocan: Placebo armPlacebo, for comparison
Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
Treatment: Administration procedures
- Biomarker GILZ: Corticosteroid armTreatment being tested
Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
Treatment: Administration procedures
- Biomarker GILZ: Placebo armPlacebo, for comparison
Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
Treatment: Administration procedures
- Biomarker CPD: Corticosteroid armTreatment being tested
Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
Treatment: Administration procedures
- Biomarker CPD: Placebo armPlacebo, for comparison
Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
Treatment: Administration procedures
- Biomarker Transcriptomic SRS: Corticosteroid armTreatment being tested
Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
Treatment: Administration procedures
- Biomarker Transcriptomic SRS: Placebo armPlacebo, for comparison
Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
Treatment: Administration procedures
- Biomarker Endotype B: Corticosteroid armTreatment being tested
Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
Treatment: Administration procedures
- Biomarker Endotype B: Placebo armPlacebo, for comparison
Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
Treatment: Administration procedures
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicentre Concealed-Allocation Multi-arms Blinded Randomized Controlled Trial to Identify the Best Sepsis Population for Corticotherapy
- Publications
- Record updated
- 1 October 2025